Investigational drug · Phase 3
D07001-Softgel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Biliary Tract Cancer (BTC).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "D07001-Softgel"
First trial start
2026
Jun 9, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "D07001-Softgel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Biliary Tract Cancer (BTC)
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "D07001-Softgel" as an intervention, largest first.
- D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract CancerPivotal-lookingRecruiting
InnoPharmax Inc.Industry
NCT06622057 · 240 participants (planned) · Start Jun 9, 2026 · Primary completion Dec 31, 2028
Drug: D07001-Softgel Capsules; Placebo · For: Biliary Tract Cancer (BTC)
Sites: Tucson, Arizona; Miami Beach, Florida; Cleveland, Ohio · 5 sites in all
- Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerPivotal-lookingTerminated
InnoPharmax Inc.Industry
NCT05065957 · 19 participants · Start Mar 29, 2022 · Primary completion Jul 31, 2025
Drug: D07001-softgel capsules + Xeloda (or TS-1); mFOLFOX · For: Biliary Tract Cancer
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taipei, Taiwan · 5 sites in all
InnoPharmax Inc.Industry
NCT03531320 · 19 participants · Start Aug 6, 2018 · Primary completion Dec 28, 2020
Drug: D07001-softgel capsules · For: Gastrointestinal Cancer; Biliary Tract Cancer
Sites: Taichung, Taiwan; Tainan, Taiwan; Taipei, Taiwan · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors.
Chiang NJ, Lee JH, Chen MH, et al. · Oncologist 2025
Also in development for Biliary Tract Cancer (BTC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.